TuHURA Biosciences Reports 2025 Year-End Financials: Clinical Pipeline Momentum Drives Strategic Focus TuHURA Biosciences, Inc. (NASDAQ: HURA), a Phase 3 immuno-oncology company, has released its financial results for the fourth …
Tag: